Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 16 studies | 26% ± 7% | |
CD16-positive, CD56-dim natural killer cell, human | 9 studies | 34% ± 16% | |
cardiac muscle cell | 6 studies | 68% ± 20% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
heart | 4 studies | 31% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 86% | 968.25 | 2277 / 2642 | 99% | 6.77 | 700 / 705 |
kidney | 76% | 573.78 | 68 / 89 | 90% | 3.53 | 810 / 901 |
prostate | 58% | 567.15 | 142 / 245 | 76% | 3.41 | 381 / 502 |
muscle | 100% | 51675.82 | 803 / 803 | 0% | 0 | 0 / 0 |
heart | 100% | 55005.41 | 859 / 861 | 0% | 0 | 0 / 0 |
spleen | 93% | 969.63 | 225 / 241 | 0% | 0 | 0 / 0 |
adrenal gland | 21% | 115.35 | 53 / 258 | 71% | 2.23 | 163 / 230 |
thymus | 4% | 32.37 | 26 / 653 | 67% | 2.17 | 408 / 605 |
esophagus | 45% | 487.33 | 647 / 1445 | 23% | 0.50 | 43 / 183 |
eye | 0% | 0 | 0 / 0 | 68% | 1.61 | 54 / 80 |
lung | 32% | 286.71 | 186 / 578 | 34% | 0.76 | 387 / 1155 |
pancreas | 2% | 9.46 | 6 / 328 | 56% | 0.99 | 100 / 178 |
uterus | 24% | 125.88 | 41 / 170 | 32% | 1.55 | 148 / 459 |
intestine | 20% | 116.89 | 197 / 966 | 33% | 0.56 | 174 / 527 |
skin | 17% | 117.23 | 299 / 1809 | 37% | 0.94 | 173 / 472 |
tonsil | 0% | 0 | 0 / 0 | 51% | 1.46 | 23 / 45 |
bladder | 29% | 169.19 | 6 / 21 | 21% | 0.43 | 104 / 504 |
liver | 24% | 124.45 | 54 / 226 | 22% | 0.61 | 91 / 406 |
stomach | 7% | 35.11 | 25 / 359 | 31% | 0.53 | 89 / 286 |
breast | 13% | 103.94 | 58 / 459 | 21% | 1.82 | 238 / 1118 |
lymph node | 0% | 0 | 0 / 0 | 31% | 0.83 | 9 / 29 |
peripheral blood | 31% | 719.66 | 286 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 27% | 411.96 | 355 / 1335 | 0% | 0 | 0 / 0 |
ovary | 8% | 40.56 | 15 / 180 | 10% | 0.17 | 42 / 430 |
adipose | 6% | 35.06 | 68 / 1204 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0002074 | Biological process | extraocular skeletal muscle development |
GO_0045214 | Biological process | sarcomere organization |
GO_0006936 | Biological process | muscle contraction |
GO_0031430 | Cellular component | M band |
GO_0032982 | Cellular component | myosin filament |
GO_0005739 | Cellular component | mitochondrion |
GO_0019900 | Molecular function | kinase binding |
GO_0005515 | Molecular function | protein binding |
GO_0008307 | Molecular function | structural constituent of muscle |
Gene name | MYOM2 |
Protein name | Myomesin-2 (165 kDa connectin-associated protein) (165 kDa titin-associated protein) (M-protein) (Myomesin family member 2) Myomesin-2 Myomesin 2 |
Synonyms | |
Description | FUNCTION: Major component of the vertebrate myofibrillar M band. Binds myosin, titin, and light meromyosin. This binding is dose dependent. |
Accessions | ENST00000616680.2 A0A0J9YVV7 ENST00000523438.1 P54296 ENST00000633850.1 ENST00000262113.9 E7EWH9 |